Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes
- PMID: 23075228
- PMCID: PMC3593165
- DOI: 10.1111/dme.12039
Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes
Abstract
It has become widely accepted that Type 2 diabetes is inevitably life-long, with irreversible and progressive beta cell damage. However, the restoration of normal glucose metabolism within days after bariatric surgery in the majority of people with Type 2 diabetes disproves this concept. There is now no doubt that this reversal of diabetes depends upon the sudden and profound decrease in food intake, and does not relate to any direct surgical effect. The Counterpoint study demonstrated that normal glucose levels and normal beta cell function could be restored by a very low calorie diet alone. Novel magnetic resonance methods were applied to measure intra-organ fat. The results showed two different time courses: a) resolution of hepatic insulin sensitivity within days along with a rapid fall in liver fat and normalisation of fasting glucose levels; and b) return of normal beta cell insulin secretion over weeks in step with a fall in pancreas fat. Now that it has been possible to observe the pathophysiological events during reversal of Type 2 diabetes, the reverse time course of events which determine the onset of the condition can be identified. The twin cycle hypothesis postulates that chronic calorie excess leads to accumulation of liver fat with eventual spill over into the pancreas. These self-reinforcing cycles between liver and pancreas eventually cause metabolic inhibition of insulin secretion after meals and onset of hyperglycaemia. It is now clear that Type 2 diabetes is a reversible condition of intra-organ fat excess to which some people are more susceptible than others.
© 2012 The Author. Diabetic Medicine © 2012 Diabetes UK.
Figures
![FIGURE 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3593165/bin/dme0030-0267-f1.gif)
![FIGURE 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3593165/bin/dme0030-0267-f2.gif)
![FIGURE 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3593165/bin/dme0030-0267-f3.gif)
![FIGURE 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3593165/bin/dme0030-0267-f4.gif)
![FIGURE 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3593165/bin/dme0030-0267-f5.gif)
![FIGURE 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3593165/bin/dme0030-0267-f6.gif)
![FIGURE 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3593165/bin/dme0030-0267-f7.gif)
![FIGURE 8](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3593165/bin/dme0030-0267-f8.gif)
![FIGURE 9](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3593165/bin/dme0030-0267-f9.gif)
Similar articles
-
Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.Diabetologia. 2011 Oct;54(10):2506-14. doi: 10.1007/s00125-011-2204-7. Epub 2011 Jun 9. Diabetologia. 2011. PMID: 21656330 Free PMC article. Clinical Trial.
-
Calorie restriction and not glucagon-like peptide-1 explains the acute improvement in glucose control after gastric bypass in Type 2 diabetes.Diabet Med. 2016 Dec;33(12):1723-1731. doi: 10.1111/dme.13257. Epub 2016 Oct 8. Diabet Med. 2016. PMID: 27589584 Clinical Trial.
-
Overnutrition, Hyperinsulinemia and Ectopic Fat: It Is Time for A Paradigm Shift in the Management of Type 2 Diabetes.Int J Mol Sci. 2024 May 17;25(10):5488. doi: 10.3390/ijms25105488. Int J Mol Sci. 2024. PMID: 38791525 Free PMC article. Review.
-
Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery.Cell Metab. 2018 Oct 2;28(4):547-556.e3. doi: 10.1016/j.cmet.2018.07.003. Epub 2018 Aug 2. Cell Metab. 2018. PMID: 30078554 Clinical Trial.
-
Understanding the mechanisms of reversal of type 2 diabetes.Lancet Diabetes Endocrinol. 2019 Sep;7(9):726-736. doi: 10.1016/S2213-8587(19)30076-2. Epub 2019 May 13. Lancet Diabetes Endocrinol. 2019. PMID: 31097391 Review.
Cited by
-
The Description and Prediction of Incidence, Prevalence, Mortality, Disability-Adjusted Life Years Cases, and Corresponding Age-Standardized Rates for Global Diabetes.J Epidemiol Glob Health. 2023 Sep;13(3):566-576. doi: 10.1007/s44197-023-00138-9. Epub 2023 Jul 3. J Epidemiol Glob Health. 2023. PMID: 37400673 Free PMC article.
-
Low-Carbohydrate Diet Scores and Mortality Among Adults With Incident Type 2 Diabetes.Diabetes Care. 2023 Apr 1;46(4):874-884. doi: 10.2337/dc22-2310. Diabetes Care. 2023. PMID: 36787923 Free PMC article.
-
Development and validation of a nomogram model for individualized prediction of hypertension risk in patients with type 2 diabetes mellitus.Sci Rep. 2023 Jan 23;13(1):1298. doi: 10.1038/s41598-023-28059-4. Sci Rep. 2023. PMID: 36690699 Free PMC article.
-
Body weight, diabetes incidence vascular events and survival 15 years after very low calorie diet in community medical clinics in the UK.BMJ Nutr Prev Health. 2022 Mar 4;5(1):55-61. doi: 10.1136/bmjnph-2021-000363. eCollection 2022. BMJ Nutr Prev Health. 2022. PMID: 35814720 Free PMC article.
-
Reversal and Remission of T2DM - An Update for Practitioners.Vasc Health Risk Manag. 2022 Jun 14;18:417-443. doi: 10.2147/VHRM.S345810. eCollection 2022. Vasc Health Risk Manag. 2022. PMID: 35726218 Free PMC article. Review.
References
-
- Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc. 1999;281:2005–2012. - PubMed
-
- Davies NJ. Type 2 and you. Balance. 2012 Available at http://www.diabetes.org.uk/How_we_help/Magazines/Balance/Past-issues/Bal... Last accessed 22 October 2012.
-
- UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–1258. - PubMed
-
- Cnop M, Vidal J, Hull RL, Utzschneider KM, Carr DB, Schraw T, et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care. 2007;30:677–682. - PubMed
-
- Festa A, Williams K, D'Agostino R, Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes. 2006;55:1114–1120. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical